RecruitingPhase 2NCT05613452

Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer

Prospective Phase II Clinical Study of Carbon Ion Beam Stereotactic Radiotherapy for Peripheral Type Early-stage Non-small Cell Lung Cancer


Sponsor

Shanghai Proton and Heavy Ion Center

Enrollment

43 participants

Start Date

Sep 29, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To investigate the efficacy of carbon ion therapy for stage Ia-IIa primary peripheral non-small cell lung cancer (NSCLC). The primary endpoint was progression-free survival (PFS), and the secondary endpoint was local control rate, overall survival (OS) and toxicities.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing carbon ion therapy — a precise type of radiation — for people with early-stage non-small cell lung cancer located away from major airways and blood vessels, who are unable or unwilling to have surgery. **You may be eligible if...** - You are between 18 and 80 years old - You have confirmed early-stage non-small cell lung cancer (stage Ia–IIa) that has not spread to lymph nodes or other organs - Your tumor is far enough from the esophagus, main airway, spinal cord, heart, and large blood vessels - You are medically unable to have surgery, or you have chosen not to have surgery - Your blood counts, lung, liver, and kidney function meet the required levels **You may NOT be eligible if...** - You have more than one primary tumor - Your cancer has spread to other parts of the body - Your general health is too poor to tolerate radiation treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONCarbon ion beam radiotherapy

Patients receive carbon ion radiotherapy of 12GyE per fraction, totally 4 fractions. Patients with tumors ≥4cm should receive at least 4 cycles of platinum-based doublet chemotherapy.


Locations(1)

Shanghai Proton and Heavy Ion Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05613452


Related Trials